ID   AOFB_HUMAN              Reviewed;         520 AA.
AC   P27338; B2R6R3; B7Z5H3; D3DWC3; Q7Z6S2;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 182.
DE   RecName: Full=Amine oxidase [flavin-containing] B;
DE            EC=1.4.3.4;
DE   AltName: Full=Monoamine oxidase type B;
DE            Short=MAO-B;
GN   Name=MAOB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2023912; DOI=10.1073/pnas.88.9.3637;
RA   Grimsby J., Chen K., Wang L.J., Lan N.C., Shih J.C.;
RT   "Human monoamine oxidase A and B genes exhibit identical exon-intron
RT   organization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:3637-3641(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3387449; DOI=10.1073/pnas.85.13.4934;
RA   Bach A.W.J., Lan N.C., Johnson D.L., Abell C.W., Bembenek M.E.,
RA   Kwan S.W., Seeburg P.H., Shih J.C.;
RT   "cDNA cloning of human liver monoamine oxidase A and B: molecular
RT   basis of differences in enzymatic properties.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:4934-4938(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8515265; DOI=10.1111/j.1471-4159.1993.tb03554.x;
RA   Chen K., Wu H.F., Shih J.C.;
RT   "The deduced amino acid sequences of human platelet and frontal cortex
RT   monoamine oxidase B are identical.";
RL   J. Neurochem. 61:187-190(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-15.
RX   PubMed=1432104;
RA   Zhu Q.S., Grimsby J.S., Chen K., Shih J.C.;
RT   "Promoter organization and activity of human monoamine oxidase (MAO) A
RT   and B genes.";
RL   J. Neurosci. 12:4437-4446(1992).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-17, ACETYLATION AT SER-2, AND MASS SPECTROMETRY.
RX   PubMed=11049757; DOI=10.1006/prep.2000.1309;
RA   Newton-Vinson P., Hubalek F., Edmondson D.E.;
RT   "High-level expression of human liver monoamine oxidase B in Pichia
RT   pastoris.";
RL   Protein Expr. Purif. 20:334-345(2000).
RN   [9]
RP   PROTEIN SEQUENCE OF 371-391, AND MUTAGENESIS OF THR-158; HIS-382;
RP   LYS-386; CYS-389 AND SER-394.
RX   PubMed=8665924; DOI=10.1111/j.1432-1033.1996.00996.x;
RA   Cesura A.M., Gottowik J., Lahm H.-W., Lang G., Imhof R., Malherbe P.,
RA   Roethlisberger U., Da Prada M.;
RT   "Investigation on the structure of the active site of monoamine
RT   oxidase-B by affinity labeling with the selective inhibitor lazabemide
RT   and by site-directed mutagenesis.";
RL   Eur. J. Biochem. 236:996-1002(1996).
RN   [10]
RP   MUTAGENESIS OF CYS-5; CYS-156; CYS-172; CYS-192; CYS-297; CYS-312;
RP   CYS-365; CYS-389 AND CYS-397.
RX   PubMed=8316221;
RA   Wu H.F., Chen K., Shih J.C.;
RT   "Site-directed mutagenesis of monoamine oxidase A and B: role of
RT   cysteines.";
RL   Mol. Pharmacol. 43:888-893(1993).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   PubMed=11753429; DOI=10.1038/nsb732;
RA   Binda C., Newton-Vinson P., Hubalek F., Edmondson D.E., Mattevi A.;
RT   "Structure of human monoamine oxidase B, a drug target for the
RT   treatment of neurological disorders.";
RL   Nat. Struct. Biol. 9:22-26(2002).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) IN COMPLEXES WITH INHIBITORS.
RX   PubMed=12913124; DOI=10.1073/pnas.1633804100;
RA   Binda C., Li M., Hubalek F., Restelli N., Edmondson D.E., Mattevi A.;
RT   "Insights into the mode of inhibition of human mitochondrial monoamine
RT   oxidase B from high-resolution crystal structures.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:9750-9755(2003).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) IN COMPLEXES WITH INHIBITORS.
RX   PubMed=15027868; DOI=10.1021/jm031087c;
RA   Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D.E.,
RA   Mattevi A.;
RT   "Crystal structures of monoamine oxidase B in complex with four
RT   inhibitors of the N-propargylaminoindan class.";
RL   J. Med. Chem. 47:1767-1774(2004).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF MUTANT PHE-199 IN COMPLEXES
RP   WITH INHIBITORS.
RX   PubMed=15710600; DOI=10.1074/jbc.M500949200;
RA   Hubalek F., Binda C., Khalil A., Li M., Mattevi A., Castagnoli N.,
RA   Edmondson D.E.;
RT   "Demonstration of isoleucine 199 as a structural determinant for the
RT   selective inhibition of human monoamine oxidase B by specific
RT   reversible inhibitors.";
RL   J. Biol. Chem. 280:15761-15766(2005).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEXES WITH INHIBITORS.
RX   PubMed=16366596; DOI=10.1021/jm0506266;
RA   Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D.E.,
RA   Mattevi A.;
RT   "Binding of rasagiline-related inhibitors to human monoamine oxidases:
RT   a kinetic and crystallographic analysis.";
RL   J. Med. Chem. 48:8148-8154(2005).
CC   -!- FUNCTION: Catalyzes the oxidative deamination of biogenic and
CC       xenobiotic amines and has important functions in the metabolism of
CC       neuroactive and vasoactive amines in the central nervous system
CC       and peripheral tissues. MAOB preferentially degrades benzylamine
CC       and phenylethylamine.
CC   -!- CATALYTIC ACTIVITY: RCH(2)NHR' + H(2)O + O(2) = RCHO + R'NH(2) +
CC       H(2)O(2).
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC   -!- SUBUNIT: Monomer, homo- or heterodimer (containing two subunits of
CC       similar size). Each subunit contains a covalently bound flavin.
CC       Enzymatically active as monomer (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane; Single-pass
CC       type IV membrane protein; Cytoplasmic side.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P27338-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P27338-2; Sequence=VSP_057047, VSP_057048, VSP_057049;
CC         Note=No experimental confirmation available.;
CC   -!- MASS SPECTROMETRY: Mass=59474; Mass_error=14.0;
CC       Method=Electrospray; Range=2-520;
CC       Evidence={ECO:0000269|PubMed:11049757};
CC   -!- SIMILARITY: Belongs to the flavin monoamine oxidase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=MAOB";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Monoamine oxidase entry;
CC       URL="https://en.wikipedia.org/wiki/Monoamine_oxidase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S62734; AAB27229.1; -; mRNA.
DR   EMBL; M69135; AAA59551.1; -; Genomic_DNA.
DR   EMBL; AK298942; BAH12909.1; -; mRNA.
DR   EMBL; AK312679; BAG35560.1; -; mRNA.
DR   EMBL; M69177; AAA59550.1; -; mRNA.
DR   EMBL; M89637; AAB46386.1; -; Genomic_DNA.
DR   EMBL; AL008709; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL020990; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX537148; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z95125; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471141; EAW59378.1; -; Genomic_DNA.
DR   EMBL; CH471141; EAW59380.1; -; Genomic_DNA.
DR   CCDS; CCDS14261.1; -. [P27338-1]
DR   PIR; JH0817; JH0817.
DR   RefSeq; NP_000889.3; NM_000898.4. [P27338-1]
DR   UniGene; Hs.654473; -.
DR   PDB; 1GOS; X-ray; 3.00 A; A/B=2-520.
DR   PDB; 1H8R; Model; -; A=5-459.
DR   PDB; 1OJ9; X-ray; 2.30 A; A/B=2-520.
DR   PDB; 1OJA; X-ray; 1.70 A; A/B=2-520.
DR   PDB; 1OJC; X-ray; 2.40 A; A/B=2-520.
DR   PDB; 1OJD; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/L=2-520.
DR   PDB; 1S2Q; X-ray; 2.07 A; A/B=1-520.
DR   PDB; 1S2Y; X-ray; 2.12 A; A/B=1-520.
DR   PDB; 1S3B; X-ray; 1.65 A; A/B=1-520.
DR   PDB; 1S3E; X-ray; 1.60 A; A/B=1-520.
DR   PDB; 2BK3; X-ray; 1.80 A; A/B=2-520.
DR   PDB; 2BK4; X-ray; 1.90 A; A/B=2-520.
DR   PDB; 2BK5; X-ray; 1.83 A; A/B=1-520.
DR   PDB; 2BYB; X-ray; 2.20 A; A/B=2-520.
DR   PDB; 2C64; X-ray; 2.20 A; A/B=2-520.
DR   PDB; 2C65; X-ray; 1.70 A; A/B=2-520.
DR   PDB; 2C66; X-ray; 2.50 A; A/B=2-520.
DR   PDB; 2C67; X-ray; 1.70 A; A/B=2-520.
DR   PDB; 2C70; X-ray; 2.06 A; A/B=2-520.
DR   PDB; 2C72; X-ray; 2.00 A; A/B=2-520.
DR   PDB; 2C73; X-ray; 2.20 A; A/B=2-520.
DR   PDB; 2C75; X-ray; 1.70 A; A/B=2-520.
DR   PDB; 2C76; X-ray; 1.70 A; A/B=2-520.
DR   PDB; 2V5Z; X-ray; 1.60 A; A/B=2-520.
DR   PDB; 2V60; X-ray; 2.00 A; A/B=2-520.
DR   PDB; 2V61; X-ray; 1.70 A; A/B=2-520.
DR   PDB; 2VRL; X-ray; 2.40 A; A/B=1-520.
DR   PDB; 2VRM; X-ray; 2.30 A; A/B=1-520.
DR   PDB; 2VZ2; X-ray; 2.30 A; A/B=1-520.
DR   PDB; 2XCG; X-ray; 1.90 A; A/B=1-520.
DR   PDB; 2XFN; X-ray; 1.60 A; A/B=1-520.
DR   PDB; 2XFO; X-ray; 2.10 A; A/B=1-520.
DR   PDB; 2XFP; X-ray; 1.66 A; A/B=1-520.
DR   PDB; 2XFQ; X-ray; 2.20 A; A/B=1-520.
DR   PDB; 2XFU; X-ray; 2.20 A; A/B=2-520.
DR   PDB; 3PO7; X-ray; 1.80 A; A/B=1-520.
DR   PDB; 3ZYX; X-ray; 2.20 A; A/B=2-520.
DR   PDB; 4A79; X-ray; 1.89 A; A/B=1-520.
DR   PDB; 4A7A; X-ray; 1.70 A; A/B=1-520.
DR   PDB; 4CRT; X-ray; 1.80 A; A/B=1-520.
DR   PDB; 5MRL; X-ray; 2.42 A; A/B=1-520.
DR   PDBsum; 1GOS; -.
DR   PDBsum; 1H8R; -.
DR   PDBsum; 1OJ9; -.
DR   PDBsum; 1OJA; -.
DR   PDBsum; 1OJC; -.
DR   PDBsum; 1OJD; -.
DR   PDBsum; 1S2Q; -.
DR   PDBsum; 1S2Y; -.
DR   PDBsum; 1S3B; -.
DR   PDBsum; 1S3E; -.
DR   PDBsum; 2BK3; -.
DR   PDBsum; 2BK4; -.
DR   PDBsum; 2BK5; -.
DR   PDBsum; 2BYB; -.
DR   PDBsum; 2C64; -.
DR   PDBsum; 2C65; -.
DR   PDBsum; 2C66; -.
DR   PDBsum; 2C67; -.
DR   PDBsum; 2C70; -.
DR   PDBsum; 2C72; -.
DR   PDBsum; 2C73; -.
DR   PDBsum; 2C75; -.
DR   PDBsum; 2C76; -.
DR   PDBsum; 2V5Z; -.
DR   PDBsum; 2V60; -.
DR   PDBsum; 2V61; -.
DR   PDBsum; 2VRL; -.
DR   PDBsum; 2VRM; -.
DR   PDBsum; 2VZ2; -.
DR   PDBsum; 2XCG; -.
DR   PDBsum; 2XFN; -.
DR   PDBsum; 2XFO; -.
DR   PDBsum; 2XFP; -.
DR   PDBsum; 2XFQ; -.
DR   PDBsum; 2XFU; -.
DR   PDBsum; 3PO7; -.
DR   PDBsum; 3ZYX; -.
DR   PDBsum; 4A79; -.
DR   PDBsum; 4A7A; -.
DR   PDBsum; 4CRT; -.
DR   PDBsum; 5MRL; -.
DR   ProteinModelPortal; P27338; -.
DR   SMR; P27338; -.
DR   BioGrid; 110302; 5.
DR   IntAct; P27338; 3.
DR   MINT; MINT-3010688; -.
DR   STRING; 9606.ENSP00000367309; -.
DR   BindingDB; P27338; -.
DR   ChEMBL; CHEMBL2039; -.
DR   DrugBank; DB08176; (1Z)-4-(4-FLUOROPHENYL)-2-METHYLIDENEBUTAN-1-IMINE.
DR   DrugBank; DB08516; (S)-(+)-2-[4-(FLUOROBENZYLOXY-BENZYLAMINO)PROPIONAMIDE].
DR   DrugBank; DB08480; 4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN.
DR   DrugBank; DB01472; 4-Methoxyamphetamine.
DR   DrugBank; DB04307; 5-Hydroxy-N-Propargyl-1(R)-Aminoindan.
DR   DrugBank; DB07512; 7-[(3-CHLOROBENZYL)OXY]-2-OXO-2H-CHROMENE-4-CARBALDEHYDE.
DR   DrugBank; DB07513; 7-[(3-CHLOROBENZYL)OXY]-4-[(METHYLAMINO)METHYL]-2H-CHROMEN-2-ONE.
DR   DrugBank; DB00915; Amantadine.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB04889; Bicifadine.
DR   DrugBank; DB01445; Bufotenine.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB01363; Ephedra.
DR   DrugBank; DB02509; Farnesol.
DR   DrugBank; DB03147; Flavin adenine dinucleotide.
DR   DrugBank; DB00614; Furazolidone.
DR   DrugBank; DB04818; Iproniazid.
DR   DrugBank; DB02095; Isatin.
DR   DrugBank; DB01247; Isocarboxazid.
DR   DrugBank; DB04147; Lauryl Dimethylamine-N-Oxide.
DR   DrugBank; DB00601; Linezolid.
DR   DrugBank; DB01577; Methamphetamine.
DR   DrugBank; DB01442; MMDA.
DR   DrugBank; DB01171; Moclobemide.
DR   DrugBank; DB08082; N-(2-AMINOETHYL)-P-CHLOROBENZAMIDE.
DR   DrugBank; DB04677; N-METHYL-N-[(1R)-1-METHYL-2-PHENYLETHYL]PROP-2-EN-1-AMINE.
DR   DrugBank; DB02211; N-Methyl-N-Propargyl-1(R)-Aminoindan.
DR   DrugBank; DB03894; N-Propargyl-1(S)-Aminoindan.
DR   DrugBank; DB08804; Nandrolone decanoate.
DR   DrugBank; DB04820; Nialamide.
DR   DrugBank; DB00184; Nicotine.
DR   DrugBank; DB04821; Nomifensine.
DR   DrugBank; DB01626; Pargyline.
DR   DrugBank; DB00780; Phenelzine.
DR   DrugBank; DB00191; Phentermine.
DR   DrugBank; DB00721; Procaine.
DR   DrugBank; DB01168; Procarbazine.
DR   DrugBank; DB01367; Rasagiline.
DR   DrugBank; DB01037; Selegiline.
DR   DrugBank; DB01104; Sertraline.
DR   DrugBank; DB00752; Tranylcypromine.
DR   DrugBank; DB04832; Zimelidine.
DR   DrugBank; DB00909; Zonisamide.
DR   GuidetoPHARMACOLOGY; 2490; -.
DR   iPTMnet; P27338; -.
DR   PhosphoSitePlus; P27338; -.
DR   BioMuta; MAOB; -.
DR   DMDM; 113980; -.
DR   EPD; P27338; -.
DR   MaxQB; P27338; -.
DR   PaxDb; P27338; -.
DR   PeptideAtlas; P27338; -.
DR   PRIDE; P27338; -.
DR   DNASU; 4129; -.
DR   Ensembl; ENST00000378069; ENSP00000367309; ENSG00000069535. [P27338-1]
DR   GeneID; 4129; -.
DR   KEGG; hsa:4129; -.
DR   UCSC; uc004dfz.5; human. [P27338-1]
DR   CTD; 4129; -.
DR   DisGeNET; 4129; -.
DR   GeneCards; MAOB; -.
DR   HGNC; HGNC:6834; MAOB.
DR   HPA; CAB037200; -.
DR   HPA; HPA002328; -.
DR   MIM; 309860; gene.
DR   neXtProt; NX_P27338; -.
DR   OpenTargets; ENSG00000069535; -.
DR   PharmGKB; PA237; -.
DR   eggNOG; KOG0029; Eukaryota.
DR   eggNOG; ENOG410XSNC; LUCA.
DR   GeneTree; ENSGT00730000110903; -.
DR   HOGENOM; HOG000221615; -.
DR   HOVERGEN; HBG004255; -.
DR   InParanoid; P27338; -.
DR   KO; K00274; -.
DR   OMA; WESRARM; -.
DR   OrthoDB; EOG091G0G7P; -.
DR   PhylomeDB; P27338; -.
DR   TreeFam; TF313314; -.
DR   BioCyc; MetaCyc:HS00966-MONOMER; -.
DR   BRENDA; 1.4.3.4; 2681.
DR   Reactome; R-HSA-141333; Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB.
DR   SABIO-RK; P27338; -.
DR   ChiTaRS; MAOB; human.
DR   EvolutionaryTrace; P27338; -.
DR   GeneWiki; Monoamine_oxidase_B; -.
DR   GenomeRNAi; 4129; -.
DR   PRO; PR:P27338; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000069535; -.
DR   CleanEx; HS_MAOB; -.
DR   Genevisible; P27338; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005740; C:mitochondrial envelope; TAS:ProtInc.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0009055; F:electron carrier activity; TAS:UniProtKB.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IEA:Ensembl.
DR   GO; GO:0008131; F:primary amine oxidase activity; TAS:Reactome.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0042420; P:dopamine catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0050665; P:hydrogen peroxide biosynthetic process; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0014063; P:negative regulation of serotonin secretion; IEA:Ensembl.
DR   GO; GO:0042135; P:neurotransmitter catabolic process; IEA:Ensembl.
DR   GO; GO:0045964; P:positive regulation of dopamine metabolic process; IEA:Ensembl.
DR   GO; GO:0010044; P:response to aluminum ion; IEA:Ensembl.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0010269; P:response to selenium ion; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0021762; P:substantia nigra development; IEP:UniProtKB.
DR   Gene3D; 3.50.50.60; -; 2.
DR   InterPro; IPR002937; Amino_oxidase.
DR   InterPro; IPR023753; FAD/NAD-binding_dom.
DR   InterPro; IPR001613; Flavin_amine_oxidase.
DR   Pfam; PF01593; Amino_oxidase; 1.
DR   PRINTS; PR00757; AMINEOXDASEF.
DR   SUPFAM; SSF51905; SSF51905; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; FAD; Flavoprotein; Membrane; Mitochondrion;
KW   Mitochondrion outer membrane; Oxidoreductase; Reference proteome;
KW   Transmembrane; Transmembrane helix.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:11049757}.
FT   CHAIN         2    520       Amine oxidase [flavin-containing] B.
FT                                /FTId=PRO_0000099859.
FT   TOPO_DOM      2    489       Cytoplasmic.
FT   TRANSMEM    490    516       Helical; Anchor for type IV membrane
FT                                protein.
FT   TOPO_DOM    517    520       Mitochondrial intermembrane.
FT   COMPBIAS     36     52       Arg/Lys-rich (basic).
FT   SITE        156    156       Important for catalytic activity.
FT   SITE        365    365       Important for catalytic activity.
FT   SITE        382    382       Important for catalytic activity.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000269|PubMed:11049757}.
FT   MOD_RES      52     52       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8BW75}.
FT   MOD_RES     397    397       S-8alpha-FAD cysteine.
FT   VAR_SEQ       1     16       Missing (in isoform 2).
FT                                /FTId=VSP_057047.
FT   VAR_SEQ     380    427       PVHYEEKNWCEEQYSGGCYTTYFPPGILTQYGRVLRQPVDR
FT                                IYFAGTE -> GSTPASGQDLLCRHRDCHTLERLHGGGCRG
FT                                RGESSPRDPACHGEDSRG (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_057048.
FT   VAR_SEQ     428    520       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_057049.
FT   MUTAGEN       5      5       C->S: No loss of activity.
FT                                {ECO:0000269|PubMed:8316221}.
FT   MUTAGEN     156    156       C->S: Complete loss of activity.
FT                                {ECO:0000269|PubMed:8316221}.
FT   MUTAGEN     158    158       T->A: Dramatic loss of activity.
FT                                {ECO:0000269|PubMed:8665924}.
FT   MUTAGEN     172    172       C->S: No loss of activity.
FT                                {ECO:0000269|PubMed:8316221}.
FT   MUTAGEN     192    192       C->S: No loss of activity.
FT                                {ECO:0000269|PubMed:8316221}.
FT   MUTAGEN     199    199       I->F: Alters specificity towards
FT                                synthetic inhibitors.
FT   MUTAGEN     297    297       C->S: No loss of activity.
FT                                {ECO:0000269|PubMed:8316221}.
FT   MUTAGEN     312    312       C->S: No loss of activity.
FT                                {ECO:0000269|PubMed:8316221}.
FT   MUTAGEN     365    365       C->S: Complete loss of activity.
FT                                {ECO:0000269|PubMed:8316221}.
FT   MUTAGEN     382    382       H->R: Significant loss of activity.
FT                                {ECO:0000269|PubMed:8665924}.
FT   MUTAGEN     386    386       K->M: No loss of activity.
FT                                {ECO:0000269|PubMed:8665924}.
FT   MUTAGEN     389    389       C->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:8316221,
FT                                ECO:0000269|PubMed:8665924}.
FT   MUTAGEN     389    389       C->S: No loss of activity.
FT                                {ECO:0000269|PubMed:8316221,
FT                                ECO:0000269|PubMed:8665924}.
FT   MUTAGEN     394    394       S->A: No loss of activity.
FT                                {ECO:0000269|PubMed:8665924}.
FT   MUTAGEN     397    397       C->S: Complete loss of activity.
FT                                {ECO:0000269|PubMed:8316221}.
FT   STRAND        6     10       {ECO:0000244|PDB:1S3E}.
FT   HELIX        14     25       {ECO:0000244|PDB:1S3E}.
FT   STRAND       30     33       {ECO:0000244|PDB:1S3E}.
FT   STRAND       35     40       {ECO:0000244|PDB:1S3E}.
FT   STRAND       45     48       {ECO:0000244|PDB:2XFN}.
FT   TURN         49     51       {ECO:0000244|PDB:1S3E}.
FT   STRAND       54     57       {ECO:0000244|PDB:1S3E}.
FT   HELIX        66     74       {ECO:0000244|PDB:1S3E}.
FT   STRAND       79     81       {ECO:0000244|PDB:1S3E}.
FT   STRAND       85     92       {ECO:0000244|PDB:1S3E}.
FT   STRAND       95     99       {ECO:0000244|PDB:1S3E}.
FT   STRAND      101    103       {ECO:0000244|PDB:1S3E}.
FT   HELIX       109    126       {ECO:0000244|PDB:1S3E}.
FT   HELIX       134    136       {ECO:0000244|PDB:1S3E}.
FT   HELIX       140    144       {ECO:0000244|PDB:1S3E}.
FT   STRAND      145    147       {ECO:0000244|PDB:2BYB}.
FT   HELIX       148    155       {ECO:0000244|PDB:1S3E}.
FT   HELIX       159    173       {ECO:0000244|PDB:1S3E}.
FT   TURN        177    179       {ECO:0000244|PDB:1S3E}.
FT   HELIX       182    190       {ECO:0000244|PDB:1S3E}.
FT   TURN        191    193       {ECO:0000244|PDB:1S3E}.
FT   HELIX       195    199       {ECO:0000244|PDB:1S3E}.
FT   STRAND      207    210       {ECO:0000244|PDB:1S3E}.
FT   HELIX       215    225       {ECO:0000244|PDB:1S3E}.
FT   HELIX       226    228       {ECO:0000244|PDB:1S3E}.
FT   STRAND      229    232       {ECO:0000244|PDB:1S3E}.
FT   STRAND      235    239       {ECO:0000244|PDB:1S3E}.
FT   STRAND      241    249       {ECO:0000244|PDB:1S3E}.
FT   STRAND      254    262       {ECO:0000244|PDB:1S3E}.
FT   HELIX       266    271       {ECO:0000244|PDB:1S3E}.
FT   STRAND      272    276       {ECO:0000244|PDB:1S3E}.
FT   HELIX       280    285       {ECO:0000244|PDB:1S3E}.
FT   STRAND      294    300       {ECO:0000244|PDB:1S3E}.
FT   HELIX       305    309       {ECO:0000244|PDB:1S3E}.
FT   STRAND      311    317       {ECO:0000244|PDB:1S3E}.
FT   STRAND      319    321       {ECO:0000244|PDB:1S3B}.
FT   STRAND      325    329       {ECO:0000244|PDB:1S3E}.
FT   STRAND      339    345       {ECO:0000244|PDB:1S3E}.
FT   HELIX       347    352       {ECO:0000244|PDB:1S3E}.
FT   HELIX       357    372       {ECO:0000244|PDB:1S3E}.
FT   HELIX       375    378       {ECO:0000244|PDB:1S3E}.
FT   STRAND      381    387       {ECO:0000244|PDB:1S3E}.
FT   HELIX       388    390       {ECO:0000244|PDB:1S3E}.
FT   TURN        392    394       {ECO:0000244|PDB:1S3E}.
FT   STRAND      396    398       {ECO:0000244|PDB:1S3E}.
FT   HELIX       406    410       {ECO:0000244|PDB:1S3E}.
FT   HELIX       411    413       {ECO:0000244|PDB:1S3E}.
FT   STRAND      421    423       {ECO:0000244|PDB:1S3E}.
FT   HELIX       426    428       {ECO:0000244|PDB:1S3E}.
FT   STRAND      430    432       {ECO:0000244|PDB:1S3E}.
FT   HELIX       436    453       {ECO:0000244|PDB:1S3E}.
FT   HELIX       459    461       {ECO:0000244|PDB:1S3E}.
FT   STRAND      470    472       {ECO:0000244|PDB:1S3E}.
FT   HELIX       481    485       {ECO:0000244|PDB:1S3E}.
FT   HELIX       489    500       {ECO:0000244|PDB:1S3E}.
SQ   SEQUENCE   520 AA;  58763 MW;  358D1025F5BCA604 CRC64;
     MSNKCDVVVV GGGISGMAAA KLLHDSGLNV VVLEARDRVG GRTYTLRNQK VKYVDLGGSY
     VGPTQNRILR LAKELGLETY KVNEVERLIH HVKGKSYPFR GPFPPVWNPI TYLDHNNFWR
     TMDDMGREIP SDAPWKAPLA EEWDNMTMKE LLDKLCWTES AKQLATLFVN LCVTAETHEV
     SALWFLWYVK QCGGTTRIIS TTNGGQERKF VGGSGQVSER IMDLLGDRVK LERPVIYIDQ
     TRENVLVETL NHEMYEAKYV ISAIPPTLGM KIHFNPPLPM MRNQMITRVP LGSVIKCIVY
     YKEPFWRKKD YCGTMIIDGE EAPVAYTLDD TKPEGNYAAI MGFILAHKAR KLARLTKEER
     LKKLCELYAK VLGSLEALEP VHYEEKNWCE EQYSGGCYTT YFPPGILTQY GRVLRQPVDR
     IYFAGTETAT HWSGYMEGAV EAGERAAREI LHAMGKIPED EIWQSEPESV DVPAQPITTT
     FLERHLPSVP GLLRLIGLTT IFSATALGFL AHKRGLLVRV
//
